Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:10/5/2009

tion ever. We finally have the financial resources to move forward on our programs. Our manufacturing facility is coming online, the global Phase III cancer trial for Multikine is being launched together with Teva Pharmaceuticals and Orient EuroPharma as two of our main partners, and we are racing to develop what we hope to be the first effective treatment for hospitalized H1N1 patients. We will continue to keep you up-to-date with any further material developments.

We thank you for your support as we move forward in several key areas.

Sincerely,

Geert Kersten

Chief Executive Officer

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BioCorRx, Inc. ( BICX ) ... a healthcare solutions organization, which focuses solely on addiction treatment; ... the U.S. alone. The Company created a unique treatment program ... compounded form for outpatient surgical implantation. The Company has exclusive ... New Zealand ) to the specially formulated Naltrexone implant. ...
(Date:3/27/2015)... , March 27, 2015 Levi & Korsinsky ... Inc. (NASDAQ: OHRP ) concerning possible violations of ... by the Company in connection with its study of ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, ... or by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... 11, 2008, the Joint Advisory Committees of the ... the Drug Safety & Risk Management Advisory Committee, ... Advisory Committee - completed a review of the ... beta-agonists (LABAs). The committees concluded that the benefits ...
... JERSEY CITY, New Jersey and PHILADELPHIA, December 11, ... microRNA-based molecular diagnostics, announced today the,commercial availability of ... now commercially available through Rosetta Genomics,CLIA-certified lab in ... To order the test, physicians may contact 1-888-522-7971, ...
Cached Medicine Technology:AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:3/29/2015)... Aliso Viejo, California (PRWEB) March 29, 2015 ... have revealed a new transition from Pixel Film Studios, ... 12 sports transitions made exclusively for Final Cut Pro ... “We’ve given our users the tools needed to effortlessly ... Film Studios introduces TranSports, a new and uniquely styled ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... loses a chunk of its tail fin, it’ll grow back ... can replace surprisingly complex body parts. A tail fin, for ... very intricate structure. It is the fish version of an ... re-grow missing tails and other appendages has fascinated veterinary and ...
... infrastructure and health facilities has revealed that 14 inmates have ... These deaths are believed to have resulted from treatment errors ... been reported that the jail infrastructure lacks adequate doctors, nurses ... for medical conditions ranging from hernia to heart disease. ...
... Research Institute, have identified a sensor that identifies glucose levels. ... It acts like a switch that increases or decreases the ... it helps to convert glucose into fat for the purpose ... X Receptor. Its dual function makes it a potential site ...
... prominently weaker and are at a risk of getting fractured ... from this disease in the U.K. Women suffer from ... drugs used to treat osteoporosis., This group of drugs plays ... menopausal age. Such women face the risk of fractures due ...
... children have reportedly died from malnutrition in Madhya Pradesh's ... a deep-rooted problem afflicting over 80,000 underprivileged children in ... village died Sunday, two-year-old Chhottu died Dec 20 though ... care of him, the activists said., ,"Both deaths ...
... cracker when she was 14 months old that left her ... peanut is enough to trigger an allergic reaction in people ... 4 1/2, in a landmark experiment that set to discover-'Could ... eventually train children's bodies to overcome severe food allergies?' ...
Cached Medicine News:Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 2Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 3Health News:Glucose Sensor That Controls Glucose Metabolism Identified 2Health News:Optimum Period is Five Years to Treat Osteoporosis: Study 2Health News:Malnutrition Kills Two Kids In Madhya Pradesh 2Health News:Is Your Child Allergic To Peanuts? 2
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
... The aplanatic lens is made ... lens system consisting of two ... clearly defined, distortion-free image. This ... for patients with macular degeneration ...
... Sheets are commonly used for orbital ... The thinner 0.4 mm sheet was ... greater flexibility and to provide a ... the orbit. It is ideally suited ...
Medicine Products: